What changed: HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
Every dated change on the records linked to HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result9Milestone8This record1
September 2026 · 1
2025 · 3
- 2025Trial resultKEYNOTE-689KEYNOTE-689 reported
Median EFS 59.
- 2025Trial resultNIVOPOSTOP (GORTEC 2018-01)NIVOPOSTOP (GORTEC 2018-01) reported
Three-year disease-free survival 63.
- 2025MilestoneKEYNOTE-689KEYNOTE-689 approval and NIVOPOSTOP: immunotherapy around surgery
A milestone in how this cancer is treated.
2024 · 2
2023 · 1
2020 · 3
- 2020Trial resultJAVELIN Head and Neck 100JAVELIN Head and Neck 100 reported
PFS HR 1.
- 2020Trial resultOral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial) reported
Median OS 7.
- 2020MilestoneJAVELIN Head and Neck 100JAVELIN Head and Neck 100: PD-L1 blockade with chemoradiation fails
A milestone in how this cancer is treated.